With novel FAP antagonists showing promising first results to mitigate FAP induced fibrosis (70), the repurposing of FAP-directed radiopharmaceuticals currently under extensive investigation for oncology may open up a new door in directing protective or restorative therapy to treat COVID-19 associated sequelae. Here, FAP is linked to COVID-19.